U NOVARTIS

Novartis India Limited Registered Office: Inspire BKC Part of 601 & 701 Bandra Kurla Complex Bandra (East) Mumbai – 400 051 Maharashtra, India Tel +91 22 50243000 Fax +91 22 50243010 Email: india.investors@novartis.com CIN No. L24200MH1947PLC006104 Website: www.novartis.in

June 24, 2020

To, The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001

Scrip code: 500672

Sub.: Annual Secretarial Compliance Report for the Financial Year ended March 31, 2020

Dear Sir/ Madam,

Pursuant to Regulation 24A of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Secretarial Compliance Report of the Company issued by Mr. K. G. Saraf, Practicing Company Secretary for the financial year 2019-20.

You are requested to kindly take the above information on record.

Thanking You.

Yours sincerely,

For Novartis India Limited

Sd/-Trivikram Guda Company Secretary & Compliance Officer

Encl.: As above

SARAF & ASSOCIATES

COMPANY SECRETARIES

www.sarafandassociates.com

423, Hind Rajasthan Building, 95, Dadasaheb Phalke Road, Dadar (C.Rly.), Mumbai - 400 014. (022) 2413 0371 / 2415 3887 (2) +91 98203 20072 (2) kamalax_saraf@hotmail.com

Secretarial Compliance Report of Novartis India Limited For the Financial Year Ended 31st March 2020 (Pursuant to SEBI- CIR/CFD/CMD/1/27/2019 Dated February 8, 2019)

I Mr. **K.G. Saraf**, Practicing Company Secretary (FCS No. 1596, Certificate of Practice No. 642) have examined:

- (a) all the documents and records made available to us and explanation provided by **Novartis India Limited** ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March 2020 ("Review Period") in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not applicable for the period under review)
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not applicable for the period under review)
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; (Not applicable for the period under review)

Secretarial Compliance Report – Novartis India Limited 2020

- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not applicable for the period under review)
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations,2013; (Not applicable for the period under review)
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

and Circulars / Guidelines issued thereunder.

and based on the above examination, I hereby report that, during the Review Period:

- (a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder
- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my/our examination of those records.
- (c) There were no actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (*including under the Standard Operating Procedures issued by SEBI through various circulars*) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder in so far as it appears from my examination of those records.
- (d) There were no items for which the listed entity was ought to have taken any actions to comply with the observations made in previous reports:

Further, in terms of SEBI circular No. CIR/CFD/CMD1/114/2019 dated October 18, 2019 in respect of Resignation of statutory auditors from listed entities and their material subsidiaries, the listed entity has suitably modified the terms of appointment of the auditor to give effect to clause 6(A) and 6(B) of the circular.

Place : Mumbai Date : 19/06/2020 FRN : S1988MH004801 UDIN : F001596B000358997 Saraf and Associates (Practising Company Secretaries)

KAMALAX GANAPAYYA SARAF igned by KAMALAX GANAPAYYA SARAF o=Personal, 23187/62722bdb5413b5135dbe18b009d48d182b57 bbe851c1,postalCode=400022, st=MAHARASHTRA, bber3rc0055b2251292ccd1385dcf82a22951b736a899 dd6d14fb83,crom=KMALAX GANAPAYYA SARAF

K.G.Saraf Proprietor FCS 1596 : CP 642